News

Sobi's 2024 Financial Insights: Growth and Future Expectations

Sobi's 2024 Financial Insights: Growth and Future Expectations

Sobi Reports on a Successful Q4 2024 Performance

Swedish Orphan Biovitrum AB (publ) (Sobi) recently shared its impressive results for the fourth quarter of 2024. With a noteworthy focus on innovation and a commitment to enhance patient care, Sobi has demonstrated solid performance across key areas of operation.

Financial Highlights of Q4 2024

Sobi's total revenue saw a remarkable increase of 9% year-over-year. When adjusted for constant exchange rates, the increase remains significant at 8%, bringing the total revenue to SEK 7,436 million compared to the previous SEK 6,844 million.

Haematology Segment Growth

In the haematology sector, revenues surged by 22% on a constant exchange rate basis, reaching SEK 4,487 million. This growth can be attributed to the strong market demand for key treatments, including:

  • Doptelet, reflecting revenues of SEK 1,147 million
  • Vonjo with a substantial contribution of SEK 416 million
  • Aspaveli/Empaveli totaling SEK 269 million
  • Altuvoct, which generated SEK 302 million in initial sales

Immunology Revenue Adjustments

Conversely, immunology revenue experienced a decline of 12%. This downturn was influenced by lower-than-expected sales of Synagis, which amounted to SEK 68 million, juxtaposed against Beyfortus royalties that provided a boost with revenues reaching SEK 1,207 million.

Overall Performance for the Full Year 2024

Reflecting on the entire year, Sobi reported a total revenue increase of 18%. After considering constant currency adjustments, the growth stands at an impressive 19%, achieving SEK 26,027 million compared to SEK 22,123 million in the previous financial year. Notably, the haematology sector outperformed, with a growth rate of 24% on a constant exchange rate basis, while immunology grew by 11%.

Profitability Metrics

The adjusted EBITA margin for the full year was recorded at 36%, excluding any items affecting comparability. Sobi’s board of directors has recommended that no dividend be declared for the 2024 financial year.

Looking Ahead: Projections for 2025

As Sobi strategizes for the year ahead, revenue growth is projected to rise by a high single-digit percentage when adjusted for constant exchange rates. Moreover, the company anticipates maintaining an adjusted EBITA margin in the mid-30s percentage of total revenue, positioning itself for continued success in the biopharmaceutical market.

Engagement with Investors and Analysts

Sobi invites investors, analysts, and the media to partake in a conference call to discuss the results in greater detail. This session is set to include a presentation followed by a Q&A segment, ensuring an interactive format for stakeholders.

Company Overview and Commitment

Sobi is dedicated to transforming the lives of individuals facing rare and debilitating diseases through specialized biopharmaceutical solutions. The company boasts a global workforce of approximately 1,800 dedicated employees across multiple continents, including North America, Europe, Asia, the Middle East, and Australia. In 2024, Sobi's revenue reached SEK 26 billion, reinforcing its position in the biopharmaceutical landscape. Their stock can be found on Nasdaq Stockholm under the ticker STO: SOBI.

Frequently Asked Questions

What were Sobi's total revenues for Q4 2024?

Total revenue for Q4 2024 was SEK 7,436 million, marking a 9% increase year-over-year.

How did haematology revenues perform?

Haematology revenue increased by 22% in Q4 2024, driven by strong sales of key treatments.

What was the adjusted EBITA margin for 2024?

The adjusted EBITA margin for the full year 2024 was reported at 36%, excluding items affecting comparability.

What are Sobi's projections for 2025?

Sobi anticipates a high single-digit revenue growth in 2025 and an EBITA margin in the mid-30s.

How can investors participate in the conference call?

Investors can join the conference call using the provided dial-in details shared in the announcement.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 261

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 305

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 210

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 156

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 460

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 256

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading

Top 5 Most Recently Viewed Articles

ANSI Electric Vehicles Standards Panel Releases New Report

Updated Category News Views 285

ANSI Electric Vehicles Standards Panel Releases New Report In a significant step towards enhancing the adoption of electric vehicles (EVs) and their infrastructure, the American National Standards Institute (ANSI) has unveiled the May 2025 Gaps Progress Report. This report is integral to understanding the collaborative efforts being made by various stakeholders to bridge...

Continue Reading
Oklahoma Startups Thrive in Catalyst Accelerator Boot Camp

Updated Category News Views 575

Catalyst Accelerator Empowers Startups through Innovative Boot Camp The Catalyst Accelerator is thrilled to unveil a significant opportunity for six emerging tech startups in Oklahoma. This new initiative, the Government Business Boot Camp, is fashioned to equip these talented companies with the insights and tools necessary to succeed in government contracting. In...

Continue Reading
Legal Action Commences for Biogen Inc. (NASDAQ: BIIB) Investors

Updated Category News Views 200

Legal Investigation for Biogen Inc. Stockholders Bragar Eagel & Squire, P.C., a reputable law firm, is currently investigating claims against Biogen Inc. (NASDAQ: BIIB) on behalf of long-term stockholders. This investigation follows the recent filing of a class action complaint aimed at holding the company accountable for alleged misleading statements regarding its...

Continue Reading
Understanding the Urgent Need for Data Governance in AI

Updated Category News Views 133

The Growing Importance of Data Governance in AI As the landscape of business evolves, the adoption of artificial intelligence (AI) in enterprises has surged, leading to significant transformations in operations, development, and knowledge work. However, this rapid integration of AI solutions has brought about new data risks that traditional technologies often overlook....

Continue Reading
Oracle's High Debt Levels Raise Concerns for Investors

Updated Category News Views 797

Oracle’s Debt Concerns Illuminate Financial Landscape In a recent analysis, a leading strategist from J.P. Morgan has drawn attention to the substantial debt levels of Oracle Corp. (NYSE: ORCL). Reporting a staggering 500% debt-to-equity ratio, Oracle’s financial commitments appear considerably higher when compared to other companies in the sector. Analysis from J.P....

Continue Reading